The combination of PTX and PMX-53 resulted in transcriptional reprogramming of tumour-associated macrophages and subsequent recruitment of CXCR3+ effector and memory CD8+ T cells to significantly reduce tumour burden, when compared to treatment with PTX alone [151]. The gene discussed is CD8A; the disease is neoplasm.